MetLife Investment Management LLC Makes New $89,000 Investment in MediWound Ltd. (NASDAQ:MDWD)

MetLife Investment Management LLC acquired a new position in MediWound Ltd. (NASDAQ:MDWD) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 4,946 shares of the biopharmaceutical company’s stock, valued at approximately $89,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Rhumbline Advisers purchased a new stake in MediWound in the 2nd quarter worth approximately $131,000. Bank of New York Mellon Corp purchased a new stake in MediWound in the 2nd quarter worth approximately $342,000. ARK Investment Management LLC purchased a new stake in MediWound in the 3rd quarter worth approximately $1,806,000. Finally, Rosalind Advisors Inc. lifted its holdings in MediWound by 22.3% in the 3rd quarter. Rosalind Advisors Inc. now owns 628,050 shares of the biopharmaceutical company’s stock worth $11,343,000 after buying an additional 114,560 shares during the period. Hedge funds and other institutional investors own 46.83% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright dropped their price objective on MediWound from $28.00 to $25.00 and set a “buy” rating for the company in a report on Wednesday, November 27th.

MediWound Stock Performance

Shares of NASDAQ:MDWD opened at $17.13 on Wednesday. MediWound Ltd. has a 52-week low of $9.88 and a 52-week high of $24.00. The firm has a market capitalization of $184.83 million, a P/E ratio of -5.91 and a beta of 0.81. The stock has a 50 day moving average price of $17.21 and a 200-day moving average price of $17.40.

MediWound (NASDAQ:MDWD) last announced its earnings results on Tuesday, November 26th. The biopharmaceutical company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.50). MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. During the same period in the prior year, the business posted ($0.24) earnings per share. On average, equities analysts forecast that MediWound Ltd. will post -2.47 EPS for the current fiscal year.

MediWound Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.